NCT04710498已完成2 期
ML42362: Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Percentage of Patients Who Complete Neoadjuvant Therapy and Were Eligible for Curative Surgical Resection
研究概览
简要总结
The purpose of this research is to evaluate whether the administration of atezolizumab before surgical resection of the tumor is feasible and to evaluate the treatment response, safety, and tolerability of atezolizumab.
详细描述
Primary Objective:
Determine the feasibility of three doses of atezolizumab prior to surgery in patients with advanced cutaneous squamous cell carcinoma
Secondary Objectives:
-
Assess response rates to neoadjuvant atezolizumab
-
Objective response rate following completion of neoadjuvant therapy based on RECIST 1.1 criteria
-
Pathological response rate (major and complete pathological response) in final surgical resection specimen
-
Assess change in surgical margins or vital structures preserved following neoadjuvant treatment
-
Assess safety and tolerability of neoadjuvant atezolizumab
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form
- •Age ≥ 18 years at time of signing Informed Consent Form
- •Histologically or cytologically confirmed squamous cell carcinoma
- •Measurable disease per RECIST v1 .1 • Note that protocol specified imaging is not necessary to fulfill this criterion. For example, a patient presenting with a visible 4cm primary lesion who has obviously RECIST evaluable disease may be considered eligible prior to baseline imaging stipulated in the protocol.
- •Availability of a representative tumor specimen that is suitable for determination of PD-L 1 immunohistochemical stain evaluation.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •Adequate hematologic and end-organ function appropriate for surgery as determined by routine preoperative evaluation. If liver function, renal function and hematologic laboratory test results are within limits acceptable for elective surgery.
- •Laboratory results that will need to be obtained within 28 days prior to initiation of study treatment:
- •Aspartate aminotransferase (AST), Alanine aminotransferas (ALT), total bilirubin, and alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN.).
- •Thyroid-stimulating hormone (TSH) < 13
- •Patients with a history of a high TSH who are receiving levothyroxine replacement at the time of eligibility evaluation and have no clinical evidence of hypothyroidism are eligible.
- •For patients receiving therapeutic anticoagulation: stable anticoagulant regimen
- •Negative hepatitis B surface antigen (HBsAg) test at screening
- •For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, as defined below: Women must remain abstinent or use contraceptive methods with a failure rate of < 1 % per year during the treatment period and for 5 months after the final dose of atezolizumab. A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state 3 (12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements. Examples of contraceptive methods with a failure rate of< 1 % per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation
- •For men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: With a female partner of childbearing potential or pregnant female partner, men must agree to remain abstinent or use a condom during the treatment period and for 5 months after the final dose of atezolizumab to avoid exposing the embryo.
排除标准
- •Patients not eligible for standard of care surgical resection
- •Distant metastatic disease
- •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) • Patients with indwelling catheters (e.g., PleurX) are allowed.
- •Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dl or corrected serum calcium > ULN)
- •Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis, etc. with the following exceptions: • Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.
- •Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
- •Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
- •Rash must cover < 10% of body surface area
- •Disease is well controlled at baseline and requires only low-potency topical corticosteroids
- •No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
- •History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
- •7 .Active tuberculosis. Patents do NOT have to be screened for tuberculosis for this trial.
- •Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
- •Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
- •Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
- •Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.
- •Prior allogeneic stem cell or solid organ transplantation
- •Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
- •Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
- •Current treatment with anti-viral therapy for hepatitis B virus (HBV)
- •Treatment with investigational therapy within 28 days prior to initiation of study treatment
- •Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti- cytotoxic T-lymphocyteassociated protein 4 (CTLA-4 ), anti-PD-1, and anti-PD-L 1 therapeutic antibodies
- •Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2)) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
- •Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (TNF)-a agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:
研究组 & 干预措施
Atezolizumab
Experimental
Subjects will receive neoadjuvant atezolizumab intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 (+/- 3 days) of each 21-day cycle for a total of 3 doses prior to surgery, unless there is clinical or radiographic evidence of disease progression.
干预措施: Atezolizumab (Drug)
结局指标
主要结局
Percentage of Patients Who Complete Neoadjuvant Therapy and Were Eligible for Curative Surgical Resection
时间窗: 9 weeks
Percentage of patients that are able to complete 3 cycles of neoadjuvant atezolizumab and were eligible for curative surgical resection will be measured.
次要结局
- Objective Response Rate(After cycle 3 (duration of each cycle 21 days))
- Pathological Response Rate(After cycle 3 (duration of each cycle 21 days))
- Changes in Vital Structures(9 weeks)
- Changes in Surgical Margins(9 weeks)
- Safety and Tolerability of Neoadjuvant Atezolizumab(9 weeks)
研究者
Vasu Divi
Associate Professor of Otolaryngology - Head & Neck Surgery
Stanford University
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Neoadjuvant Atezolizumab in Cutaneous MelanomaCutaneous MelanomaNCT04020809The Methodist Hospital Research Institute20
终止
2 期
Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary SiteLocally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckResectable Cutaneous Squamous Cell Carcinoma of the Head and NeckStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8NCT05110781University of California, Davis1
进行中（未招募）
2 期
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckCarcinomaHead and Neck CancerCancerSquamous Cell CarcinomaNCT03708224Alain Algazi55
进行中（未招募）
1 期
Preoperative immunotherapy with atezolizumab (Tecentriq®) and tiragolumab in patients with colorectal liver metastases (CRLM) (the PURPLE trial)Colorectal liver metastases (CRLM)CTIS2022-503044-40-00niversitaetsklinikum Essen AöR18
进行中（未招募）
2 期
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).Oral Cavity Squamous Cell CarcinomaSquamous Cell CarcinomaNCT05681039M.D. Anderson Cancer Center29